Lördag 7 Juni | 13:04:06 Europe / Stockholm

Prenumeration

2025-06-02 14:58:00

BioInvent recently entered into a transaction with XOMA Royalty Corporation, selling its royalty and milestone rights for mezagitamab (TAK-079) for up to $30 million. The deal provides BioInvent with non-dilutive capital to advance its clinical pipeline, highlighting the strength of its proprietary n-CoDeR antibody platform.

Read the article at biostock.se:

https://biostock.se/en/2025/06/bioinvent-secured-up-to-30-musd-from-xoma-royalty/
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/